Reversible Covalent BTK Inhibitors for Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by Bruton tyrosine kinase (BTK) such as autoimmune diseases, inflammatory diseases, and cancer are limited by the lack of effective and selective inhibitors.
Innovation Solution
Development of reversible covalent inhibitors, specifically (R)- and (S)-2-(3-(4-amino-2-oxo-3-(4-phenoxyphenyl)-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)piperidine-1-yl) compounds that form a reversible covalent bond with the cysteine residue of BTK, providing targeted inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional BTK inhibitors are used, then BTK activity is inhibited, but the inhibitors lack selectivity and effectiveness for specific disease subtypes
Solution Approach 1:
The patent applies local quality by introducing disease-specific substituents on the core inhibitor structure. Different substituents (e.g., fluorophenyl groups, pyridine rings, purine moieties) are attached at specific positions to optimize binding affinity for BTK in different disease contexts, such as B-cell malignancies versus autoimmune conditions, thereby achieving both effectiveness and subtype specificity.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor molecules, including substituent types, steric configurations (R/S enantiomers), and electronic properties. These parameter modifications allow fine-tuning of pharmacological characteristics to match specific disease requirements while maintaining core BTK inhibitory activity.
2Reliability
If irreversible BTK inhibitors are used, then strong inhibition is achieved, but off-target effects and toxicity increase
Solution Approach 1:
The patent converts the potential harm of covalent bonding into a benefit by designing reversible covalent inhibitors that form transient bonds with BTK. The reversible nature allows the inhibitor to bind strongly during the inhibition period while automatically dissociating afterward, preventing permanent modification of the target and reducing off-target effects and toxicity associated with irreversible inhibitors.
Solution Approach 2:
The patent introduces dynamics by creating inhibitors that can reversibly bind and dissociate from BTK rather than forming permanent bonds. This dynamic interaction allows the inhibitor to adapt its binding state based on cellular conditions, maintaining strong inhibition when needed while avoiding the harmful effects of irreversible binding through controlled reversibility.
3Reliability
If existing BTK inhibitor classes are used, then BTK signaling is blocked, but the compounds lack optimal pharmacokinetic properties
Solution Approach 1:
The patent applies composite materials by combining multiple functional moieties within a single inhibitor molecule. The core structure includes a BTK-binding pharmacophore combined with specific substituents that provide desirable pharmacokinetic properties such as metabolic stability, appropriate binding affinity, and favorable solubility characteristics, achieving both signal blocking and pharmacokinetic optimization.
Solution Approach 2:
The patent uses intermediary structures in the form of linker groups and substituent moieties that mediate between the core BTK-binding functionality and the pharmacokinetic requirements. These intermediary elements (such as ester groups, amide linkages, and various substituent chains) facilitate optimal drug metabolism, distribution, and efficacy while maintaining strong BTK inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit BTK activity, offering therapeutic benefits for a wide range of diseases including autoimmune disorders, inflammatory conditions, and cancers by selectively targeting BTK, potentially reducing reliance on corticosteroids and other immunosuppressive agents.
Implementation Method 1
These compounds are reversible covalent inhibitors of BTK, i.e., they can form a reversible covalent bond with a thiol group of a cysteine residue
Data Source
AI summary
The present disclosure provides compounds that are tyrosine kinase inhibitors, in particular Bruton tyrosine kinase ("BTK") inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of BTK such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.